Effects of polyaspartic acid on pharmacokinetics of tobramycin in two strains of rat.
To provide insight into polyaspartic acid nephroprotection and differences in aminoglycoside renal toxicity between two rat strains, the single-dose pharmacokinetics of tobramycin was examined in the presence and absence of polyaspartic acid. Following a single subcutaneous 6.5-mg/kg dose of tobramycin alone, higher aminoglycoside concentrations were measured in Sprague-Dawley rats than in Fischer rats (P < 0.05). Simultaneous administration of polyaspartic acid (50 mg/kg) and tobramycin did not alter the concentrations of tobramycin in serum. The amount of tobramycin in renal tissue and the amount recovered in urine over a 24-h period were greater in both rat strains when tobramycin and polyaspartic acid were given concomitantly. In summary, polyaspartic acid did not alter the concentrations in serum achieved after a single dose of tobramycin in two different rat strains but did result in higher renal concentrations and greater urinary excretion of tobramycin.
Reinhard
M K
MK
Fujisawa Pharmaceutical Co., Deerfield, Illinois 60015.
Bekersky
I
I
Sanders
T W
TW
Harris
B J
BJ
Hottendorf
G H
GH
D000818:Animals; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D010455:Peptides / Q000097:blood / Q000494:pharmacology* / Q000652:urine; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D014031:Tobramycin / Q000493:pharmacokinetics* / Q000633:toxicity
D010455:Peptides; C017645:polyaspartate; D014031:Tobramycin